F
Arrowhead Pharmaceuticals, Inc. — Earnings Quality Grade F
ARWR · Healthcare
Major red flags
Revenue
$829M
2025
Net Income
-$2M
2025
Gross Margin
—
Free Cash Flow
$157M
01
Screening Summary
8
Passed
3
Watch
1
Failed
—
M-Score
管理层信号
最近 SEC 8-K 文件中未发现 CEO、CFO、董事会或审计负责人变动信号。
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
!
A3Revenue vs CFFO
Revenue grew 23258.2% but CFFO only 138.8%
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
✓
B2CapEx vs Revenue
CapEx growth -84.0% vs revenue 23258.2%. Normal
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✗
C1CFFO vs Net Income
CFFO < Net Income for 3 consecutive years
✓
C2Free Cash Flow
FCF $0.2B, FCF/NI = -96.19
✓
C3Accruals Ratio
Accruals ratio = -13.1%. Low accruals
✓
C4Cash vs Debt
Cash $0.9B covers debt $0.4B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
Goodwill+Intangibles $0.0B = 1% of equity. Manageable
!
D2Leverage
Interest coverage = 1.1x (<2x). Financial stress
✓
D3Soft Asset Growth
Other assets -69.0% vs revenue 23258.2%. Normal
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
!
E1Serial Acquirer FCF
FCF after acquisitions negative for 2/3 years
✓
E2Goodwill Surge
Goodwill+Intangibles change -20% YoY. Normal
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
0.99
Distress Zone0 Distress1.102.605.0+ Safe
0.5451
Liquidity
-1.1746
Cumulative profit
0.1017
Operating efficiency
0.5285
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25